secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001213900-25-024826
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix to present Proclarix clinical data at EAU congress; study of 800+ patients
--------------------------------------------------------------------------------

- Abstract accepted for 2025 European Association of Urology congress (March 21-24, Madrid).
- Presentation titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer.'
- Study includes >800 patients from Lillebaelt Hospital, University Hospital of Southern Denmark.
- Proclarix is a biomarker-based blood test; CEO notes potential to reduce biopsies.
- No financial terms disclosed; presentation scheduled March 23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025024826/0001213900-25-024826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025024826/ea0234883-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-024826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer